LINC00626 Drives Tamoxifen Resistance in Breast Cancer Cells by Interaction with UPF1

Overview

Journal Sci Rep

Date 2025 Jan 23

PMID 39848992

Authors

Hui Yuan

Lianbang Zhou

Wei Hu

Min Yang

Affiliations

Soon will be listed here.

Abstract

Although tamoxifen is commonly utilized as adjuvant therapy for Estrogen Receptor alpha (ERα)-positive breast cancer patients, approximately 30-50% of individuals treated with tamoxifen experience relapse. Therefore, it is essential to investigate additional factors besides ERα that influence the estrogen response. In this study, cross-analysis of databases were performed, and the results revealed a significant association between LINC00626 and ERα signaling as well as increased expression levels of this gene in tamoxifen-resistant cells. LINC00626 is a novel ERα-regulated long non-coding RNA (lncRNA) that has not yet been examined for its potential contribution to endocrine therapy resistance. This study revealed that the upregulation of LINC00626 in breast cancer was associated with poor overall survival in patients. Additionally, ERα signaling was found to transcriptionally regulate LINC00626 expression, thereby promoting cancer progression and enhancing resistance to tamoxifen in breast cancer cells via the regulation of UPF1 expression. Depletion of LINC00626 restored sensitivity to tamoxifen by activating the PERK-ATF4-CHOP signaling pathway via UPF1. These findings support the role of LINC00626 as a potential therapeutic target for combating tamoxifen resistance.

References

Karam R, Lou C, Kroeger H, Huang L, Lin J, Wilkinson M . The unfolded protein response is shaped by the NMD pathway. EMBO Rep. 2015; 16(5):599-609. PMC: 4428047. DOI: 10.15252/embr.201439696. View

Jordan V, OMalley B . Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol. 2007; 25(36):5815-24. DOI: 10.1200/JCO.2007.11.3886. View

Arun G, Diermeier S, Akerman M, Chang K, Wilkinson J, Hearn S . Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. Genes Dev. 2015; 30(1):34-51. PMC: 4701977. DOI: 10.1101/gad.270959.115. View

Liang Y, Zhang Y, Tan X, Qiao H, Liu S, Tang L . A lncRNA signature associated with tumor immune heterogeneity predicts distant metastasis in locoregionally advanced nasopharyngeal carcinoma. Nat Commun. 2022; 13(1):2996. PMC: 9151760. DOI: 10.1038/s41467-022-30709-6. View

Wu M, Zhang X, Zhang W, Chiou Y, Qian W, Liu X . Cancer stem cell regulated phenotypic plasticity protects metastasized cancer cells from ferroptosis. Nat Commun. 2022; 13(1):1371. PMC: 8927306. DOI: 10.1038/s41467-022-29018-9. View

Chakravarty D, Sboner A, Nair S, Giannopoulou E, Li R, Hennig S . The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat Commun. 2014; 5:5383. PMC: 4241506. DOI: 10.1038/ncomms6383. View

Prensner J, Chinnaiyan A . The emergence of lncRNAs in cancer biology. Cancer Discov. 2011; 1(5):391-407. PMC: 3215093. DOI: 10.1158/2159-8290.CD-11-0209. View

Dodson A, Parry S, Ibrahim M, Bartlett J, Pinder S, Dowsett M . Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients. J Pathol Clin Res. 2018; 4(4):262-273. PMC: 6174620. DOI: 10.1002/cjp2.112. View

Zhu C, Zhang L, Zhao S, Dai W, Xu Y, Zhang Y . UPF1 promotes chemoresistance to oxaliplatin through regulation of TOP2A activity and maintenance of stemness in colorectal cancer. Cell Death Dis. 2021; 12(6):519. PMC: 8140095. DOI: 10.1038/s41419-021-03798-2. View

10.

Karousis E, Muhlemann O . Nonsense-Mediated mRNA Decay Begins Where Translation Ends. Cold Spring Harb Perspect Biol. 2018; 11(2). PMC: 6360860. DOI: 10.1101/cshperspect.a032862. View

11.

Fang Z, Wang Y, Wang Z, Xu M, Ren S, Yang D . Is an Estrogen-Responsive LncRNA That Drives Breast Cancer through the E2F1/RB1 Pathway. Cancer Res. 2020; 80(20):4399-4413. PMC: 7572695. DOI: 10.1158/0008-5472.CAN-20-1031. View

12.

Brown R, Davidson N . Adjuvant hormonal therapy for premenopausal women with breast cancer. Semin Oncol. 2006; 33(6):657-63. DOI: 10.1053/j.seminoncol.2006.08.014. View

13.

Hayes E, Lewis-Wambi J . Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA. Breast Cancer Res. 2015; 17:40. PMC: 4362832. DOI: 10.1186/s13058-015-0542-y. View

14.

Mattick J, Amaral P, Carninci P, Carpenter S, Chang H, Chen L . Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023; 24(6):430-447. PMC: 10213152. DOI: 10.1038/s41580-022-00566-8. View

15.

Wang M, Xie K, Zhao S, Jia N, Zong Y, Gu W . Aerobic exercise improves cognitive impairment in mice with type 2 diabetes by regulating the MALAT1/miR-382-3p/BDNF signaling pathway in serum-exosomes. Mol Med. 2023; 29(1):130. PMC: 10517522. DOI: 10.1186/s10020-023-00727-1. View

16.

Zhang Y, Xie X, Cheng H, Zhang Y, Li H, Zhu Y . Bisphenol A interferes with lncRNA Fhadlos2 and RUNX3 association in adolescent mouse ovary. Ecotoxicol Environ Saf. 2023; 259:115060. DOI: 10.1016/j.ecoenv.2023.115060. View

17.

Wengrod J, Martin L, Wang D, Frischmeyer-Guerrerio P, Dietz H, Gardner L . Inhibition of nonsense-mediated RNA decay activates autophagy. Mol Cell Biol. 2013; 33(11):2128-35. PMC: 3648072. DOI: 10.1128/MCB.00174-13. View

18.

Zhang S, Wang R, Wang X, Guo X, Du Y, Guo X . HBXIP is a novel regulator of the unfolded protein response that sustains tamoxifen resistance in ER+ breast cancer. J Biol Chem. 2022; 298(3):101644. PMC: 8908272. DOI: 10.1016/j.jbc.2022.101644. View

19.

Jin K, Kong X, Shah T, Penet M, Wildes F, Sgroi D . The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proc Natl Acad Sci U S A. 2011; 109(8):2736-41. PMC: 3286915. DOI: 10.1073/pnas.1018859108. View

20.

Yuan H, Yan L, Wu M, Shang Y, Guo Q, Ma X . Analysis of the Estrogen Receptor-Associated LncRNA Landscape Identifies a Role for ERLC1 in Breast Cancer Progression. Cancer Res. 2021; 82(3):391-405. DOI: 10.1158/0008-5472.CAN-21-1155. View